FDA Approves Johnson & Johnson’s Spravato Nasal Spray for Depression Treatment
FDA Approves Johnson & Johnson’s Spravato as frist Standalone Therapy for Treatment-Resistant Depression In a groundbreaking move, the Food and Drug Administration (FDA) has approved Johnson & Johnson’s nasal spray, Spravato, as the first-ever standalone therapy for adults with treatment-resistant depression. This decision marks a meaningful milestone in mental health treatment, offering new hope … Read more
